AMGN34:BVMF
Amgen Inc. BDR
78,23 BRL
arrow_downward
−1,01%(−0,80) 1D
30. ruj, 16:56:00 GMT -3 · BRL
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za AMGN34...
Otvori
78,46 BRL
Najviša
78,46 BRL
Najniža
77,85 BRL
Trž. kap.
227,88 mlr.
Prosj. kol.
375,00
Količina
118,00
52-tjed. najviša
83,06 BRL
52-tjed. najniža
47,76 BRL
Dionice u optjecaju
540,63 mil.
Broj djelatnika
32 tis.
Otvori
78,46 BRL
Najviša
78,46 BRL
Najniža
77,85 BRL
Trž. kap.
227,88 mlr.
Prosj. kol.
375,00
Količina
118,00
52-tjed. najviša
83,06 BRL
52-tjed. najniža
47,76 BRL
Dionice u optjecaju
540,63 mil.
Broj djelatnika
32 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
GuruFocus
·
prije 19 sati
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors
kalkine.ca
·
prije 1 dan
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines
Yahoo Finance
·
prije 1 dan
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead
AD HOC NEWS
·
prije 1 dan
Amgen stock draws attention after a Phase 3 trial win
Profil
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Amgen Inc. BDR – informacije
Glavni izvršni direktorRobert A. Bradway
Zaposlenici31,5 tis.
Osnovano8. tra 1980.
SjedišteThousand Oaks, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijaamgen.com